ANNOUNCEMENT 2019



WHO Collaborating Centre for Research and Training in Management of Multidrug-Resistant Tuberculosis, Latvia

The WHO Collaborating Centre for Research and Training in Management of MDR-TB (WHO CC) in Riga, Latvia was established in 2004 with the objective of providing high quality, evidence-based capacity development at all levels (individual, organizational and institutional), drawing on worldwide evidence and in line with the latest developments and WHO guidance. Capacity development activities are structured according to the latest scientific developments in practical aspects of the treatment and management of drug-resistant tuberculosis (DR-TB).

TIME	COURSE	LANGUAGE	REGISTRATION DEADLINE
28/01 01/02	Latest updates in management of TB in children	RUSSIAN	
11/03 20/03	Programmatic and clinical management of DR-TB in order to achieve sustainable development goals	ENGLISH	01/02
08/04 17/04	Programmatic and clinical management of DR-TB in order to achieve sustainable development goals	RUSSIAN	01/03
13/05 17/05	Programmatic introduction of the new and re-purposed anti-TB medicines for treatment of DR-TB Line Probe Assay technology - rapid molecular drug susceptibility test available for the diagnosis of DR-TB	RUSSIAN	03/04
19/08 28/08	Programmatic and clinical management of DR-TB in order to achieve sustainable development goals	RUSSIAN	07/07
21/10 25/10	Programmatic introduction of the new and re-purposed anti-TB medicines for treatment of DR-TB Line Probe Assay technology - rapid molecular drug susceptibility test available for the diagnosis of DR-TB	RUSSIAN	10/09

Upon request, different types of capacity development activities are designed and organised for TB laboratory management, adjuvant surgery for TB, childhood TB, effective health communication and training of trainers.



COURSE DIRECTOR: Dr. Liga Kuksa



liga.kuksa@aslimnica.lv

www.tblatvia.com

01

COURSE COORDINATORS: Ms. Liga Rusmane, Ms. Ita Sprukule

 \simeq




Programmatic and clinical management of drug resistant tuberculosis in order to achieve sustainable development goals

COURSE MODULES:




Epidemiology of TB, MDR-TB, XDR-TB and TB/HIV; social determinants, migrants and other vulnerable groups



Perspectives of the NTP's on implementing innovative diagnostics and treatment for MDR-TB

Updates on diagnosis of TB and TB drug resistance; TB diagnostic algorithm proposed by the European TB Laboratory Initiative (ELI)

Designing an effective regimen using clinical case scenarios from the field



Active drug safety monitoring and management (aDSM)

Use of shorter MDR-TB regimens in European regions; the ethical imperative to move to shorter regimens

Treatment of MDR-TB in special situations, TB/HIV co-infection

Adjuvant therapies in M/XDR-TB management: nutrition, surgery, rehabilitation

Fundamentals of infection control; FAST: a TB infection control strategy

Management of failures and chronic patients the role of palliative care

Developing models of care for MDR-TB patients; people-centered TB care

Monitoring of treatment effectiveness and outcome evaluation for TB and MDR-TB patients

Procurement and supply management (PSM)

TARGET AUDIENCE:

Clinicians, staff of national TB programs, persons responsible for diagnostics and treatment of DR-TB, from countries with high levels of DR-ТΒ

TRAINING FEE:

1700 EUR, including training materials, site visit, local transport, catering during working hours/on working days, visa invitation support.



9 business days (from Monday to Wednesday, including Saturday)



Russian/English



Additional costs: hotel accommodation (from ~ 40 EUR to ~ 80 EUR per night), international flight, visa, reduced daily allowance.



Programmatic introduction of the new and re-purposed anti-TB medicines for treatment of DR-TB

COURSE MODULES:



Epidemiology of TB, MDR-TB, XDR-TB and TB/HIV; social determinants.



Perspectives of the National Tuberculosis Program (NTP) on implementing innovative diagnostics and treatment for M/XDRTB.

Laboratory diagnosis of TB and TB drug resistance; TB diagnostic algorithm proposed by the European TB Laboratory Initiative (ELI).

Programmatic approach to the treatment of rifampicin-resistant TB (RR-TB); the role of clinicians in the introduction of new and repurposed drugs and regimens for different types of resistance.



Clinical issues in new drug introduction, regimen design, and drug-drug interactions; off-label use of new TB drugs; use in special populations.



Role of patient-centred care, support and adherence-support package; ethical considerations and informed consent; examples of patient consent.

Adjuvant therapies; the role of surgery using new and re-purposed drugs.



Drug safety; scope of safety data collection and definitions; active drug safety monitoring and management (aDSM).



Clinical management of adverse events of interest: peripheral neuropathy, myelosuppression, prolonged QT interval, optic nerve disorder (optic neuritis), hepatitis, acute kidney injury, hearing impairment, hypokalemia, and hypothyroidism.



Monitoring and evaluation requirements for the use of new and re-purposed drugs; length of therapy with new drugs.

Pharmacokinetic and minimum inhibitory concentration (MIC) variability as determinants of TB clinical outcomes in adults and children - state of the evidence.



TARGET AUDIENCE:

Clinicians, staff of national TB programs, persons responsible for diagnostics and treatment of DR-TB, from countries with high levels of DR-ΤВ

TRAINING FEE:

1200 EUR, including training materials, site visit, local transport, catering during working hours/on working days, visa invitation support



DURATION: 5 business days (from

Monday to Friday)



Russian



02



Line Probe Assay technology - rapid molecular drug susceptibility test available for the diagnosis of DR-TB

This hands-on work training was designed by combining the latest evidence and recommendations on rapid molecular diagnostic methods with practical work at the TB Supranational Reference Laboratory in Riga, Latvia

COURSE MODULES:



Epidemiology of TB, MDR-TB, XDR-TB and TB/HIV. Social determinants, migrants and other vulnerable groups.




Development of DR-TB epidemic on crossroads. Can we prevent development and spread of DR-TB?



National Tuberculosis Program (NTP) perspectives on implementing innovative diagnostics and treatment for MDR-TB.



Updates on diagnosis of TB and TB drug resistance. Proposed TB diagnostic algorithm by the European TB Laboratory Initiative (ELI).






TB Laboratory services and laboratory network.



Molecular line probe assays for the detection of mutations associated with resistance to first and second line TB drugs.



Infection control requirement for laboratories at different levels.





TARGET AUDIENCE:

TB Laboratory specialists

DURATION:
5 business days (from

Monday to Friday)



Russian



TRAINING FEE:

1280 EUR, including training materials, site visit, local transport, catering during working hours/on working days, visa invitation support Additional costs: hotel accommodation (from ~ 40 EUR to ~ 80 EUR per night), international flight, visa, reduced daily allowance.



Latest updates in management of TB in children

COURSE MODULES:



Epidemiology of TB, MDR-TB, XDR-TB and TB/HIV; social determinants, migrants and other vulnerable groups



Epidemiology of TB in children. Pathogenesis and peculiarities of childhood TB

WHO's End TB Strategy and roadmap to implement TB action plan for the European Region, 2016-2020



Updates on diagnosis of TB and TB drug resistance; TB diagnostic algorithm proposed by the European TB Laboratory Initiative (ELI)



Strategic approach to preventing and managing TB in children


Prophylaxis of TB in children, immunological diagnosis of TB infection diagnosis of TB in children

Diagnosis and treatment of TB /MDR/XDR TB in children

Developing models of care for TB in children; people-centered TB care, including ethical issues, human rights, and treatment in hospital or outpatient settings



Treatment of MDR-TB in special situations



Active drug safety monitoring and management (aDSM)



TARGET AUDIENCE:

TRAINING FEE:

invitation support

Pediatricians, TB specialists

1200 EUR, including training materials,

working hours/on working days, visa

site visit, local transport, catering during



DURATION: 5 business days (from

Monday to Friday)



Russian

Additional costs: hotel accommodation (from ~ 40 EUR to ~ 80 EUR per night), international flight, visa, reduced daily

allowance.

WHO Collaborating Centre for Research and Training in Management of MDR-TB



www.tblatvia.com